On February 23, 2020, the American Society of Retina Specialists (ASRS) warned members about the side effects of Beovu, an injectable drug used to treat wet age-related macular degeneration. The organization reported results from a study revealing side effects of retinal vasculitis and the more serious retinal artery occlusion.
An explosion of recent studies from multiple university medical centers recently exposed that the use of the prescription drug Elmiron® can result in patients’ vision failure, up to and including legal blindness. Elmiron® is the brand name for pentosane polysulfate sodium (“PPS”), a drug manufactured and distributed by Janssen Pharmaceuticals. It has been marketed for nearly twenty-five years and resulted in billions of dollars of sales for Janssen. The earliest clinical trials for Elmiron® from the 1990s revealed not only dubious efficacy, but also a hos
With 80 product liability lawsuits already filed and hundreds more likely to follow, lawyers are discussing the coordination of multi-district litigation (MDL). To date, legal action has been taken against Johnson & Johnson’s Janssen Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc., and other pharma companies.
Plaintiffs allege that these companies knowingly withheld risks connected with long-term use of the drug. Complaints list such outcomes as retinal damage and blurred and distorted vision.
After four years of litigation between plaintiffs and Johnson & Johnson, the multinational corporation agreed to the first set of major settlements. The agreement to pay $100 million will resolve more than 1,000 lawsuits in which plaintiffs allege that the talc in Johnson & Johnson’s signature baby powder causes cancer, according to a Bloomberg report. This settlement marks the first to come from almost 20,000 lawsuits.
In 2016, residents in Hoosick Falls, New York, learned that for years they had been drinking water contaminated with perfluorooctanoic acid (PFOA). One resident, Nikki Aldrich, carried her two children during this period of contamination.
Aearo Technologies’ Combat Arms earplugs were standard issue for U.S. soldiers fighting in Iraq and Afghanistan. The devices were hailed as groundbreaking technology that enabled soldiers to protect their hearing while still being able to hear commands amidst war zones.
On September 1, 2020, District Judge Edmund A. Sargus, the presiding judge for In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Prods. Liab. Litig., MDL No. 2846, issued the summary judgment ruling in the first bellwether trial. Johns v. C.R. Bard, Inc., is a Ventralight™ ST case which is a defense pick and which is set for trial on January 11, 2021. The ruling leaves intact nearly all of the plaintiff’s legal theories of relief but trimmed the scope of compensatory damages available to the plaintiff.
When drinking water supplies around Fayetteville, North Carolina proved to be contaminated, all fingers pointed to per- and polyfluoroalkyl substances (PFAS) manufactured at Chemours’ Fayetteville Works plant. U.S. Rep. Richard Hudson, R-N.C. called a roundtable meeting to discuss the pollution. The meeting included various local officials, but the A-list attendee had to have been federal Environmental Protection Agency (EPA) Administrator Andrew Wheeler.
U.S. Court of Appeals for the Ninth Circuit upheld damages awarded to a patient who suffered heart damage from C.R. Bard’s clot-stopping vein filter. The court ruled that the U.S. Food and Drug Administration’s edicts did not pre-empt Georgia’s state law underscoring a duty to warn.
In 2007, patient Sherr-Una Booker underwent a surgical procedure to place a Bard’s G2 model inferior vena cava (IVC) filter near her heart. When fragments of the filter became detached, Booker was forced to under heart revision surgery.
A class-action lawsuit might be taking shape against Geico auto insurance company. When the insurer announced its 15% “Geico Giveback” premium discount program in April, consumers understood it would reflect the dramatic reduction in driving during the COVID-19 crisis. Consumers, however, think the country’s second largest auto insurer undelivered on its promise, and they have taken legal action.
In September 2019, the U.S. Food & Drug Administration reported that at least 12 women had died from breast implant associated anaplastic large cell lymphoma (BIA-ALCL)—a rare cancer of the immune system—caused by textured breast implants and tissue expanders made by Allergan.
In a press release announcing second-quarter earnings, Bayer AG reported that it has reserved $1.47 billion (1.25 billion euros) for the potential settlement of Essure contraceptive device lawsuits filed against the company. Some of the funds set aside will be used in settlement for other lawsuits the company faces.
A federal court judge ruled on Friday, July 24, 2020, that 3M created designs for its Combat Arms Earplugs, Version 2 (CAEv2) without U.S. military input, and so the company cannot use the government contract defense at trial.
In planning their legal strategy, 3M lawyers aimed to invoke the government contract defense, which protects companies from facing liability for defective products that are designed and produced for the federal government.
On April 1, 2020, the Food and Drug Administration told companies to stop selling Zantac, and they further urged consumers to throw away any form of the heartburn medicine that might be sitting in household medicine cabinets.
Most stores had already taken Zantac, also known as ranitidine, off their shelves last September when the FDA announced that the drug contains a type of carcinogenic nitrosamine (N-nitrosodimethylamine, or NDMA).
Will the coronavirus crash the stock market? Who knows. But Peter J. Mougey says considering that “once in a lifetime” market crashes now happen once a decade, you’re better off worrying about investment issues you can control. Here, he shines a light on bad, life-ruining advice many investors get—and what you can do to recognize and avoid it.
Is Your Portfolio Still Down More Than 10 Percent in the Coronavirus Stock Market? Then Your Advisor Has Some Explaining to Do!
Peter Mougey says you should never accept the "whole market is down" excuse from your advisor. He debunks some common misconceptions about what "the market" really is, what real diversification looks like, and how to push back if you're down more than 10 percent.
Keeping Calm in the Coronavirus Market: Eight Guidelines to Help You Make Smart Decisions (at Every Age)
Peter Mougey explains how to avoid knee-jerk, fear-based reactions; how to talk to your financial advisor; and how to make sound decisions that fit your unique circumstances.
The market has been super volatile lately. With the coronavirus still wreaking havoc, economic ups and downs, and an election on the horizon, that's not likely to change any time soon. If you're retired or nearing retirement, investors' rights advocate Peter Mougey says you might want to look at a) what's happening with your performance, and b) the make-up of your portfolio.
If you’re making withdrawals from your retirement account, you need to understand the math behind your financial advisor’s strategy. Peter Mougey says you should make sure they are following three critical math rules.
Retirees who make regular withdrawals from their portfolio have specific risks that younger investors don't need to worry about. That's why it's so important to understand the math behind what you're doing—especially in a time of market turmoil like the one we're in now.